Quarterly ResultMay 12, 2026, 07:02 AM
Acumen Pharma expects ALTITUDE-AD Phase 2 results late 2026; Q1 Net Loss $20.7M
AI Summary
Acumen Pharmaceuticals reported its first quarter 2026 financial results, showing a reduced net loss of $20.7 million and decreased R&D expenses. The company provided a business update, highlighting the anticipated topline results for its ALTITUDE-AD Phase 2 study in late 2026, which is investigating sabirnetug for early Alzheimer’s disease. Additionally, Acumen plans to file an IND for a lead clinical candidate in its EBD program by mid-2027 and expects to license two EBD candidates in Q2 2026. The company's cash balance of $128.4 million as of March 31, 2026, is projected to fund operations into early 2027.
Key Highlights
- Acumen Pharmaceuticals expects topline results for its ALTITUDE-AD Phase 2 study in late 2026.
- The company targets an IND filing for a lead clinical candidate in its EBD program in mid-2027.
- Cash, cash equivalents, and marketable securities totaled $128.4 million as of March 31, 2026.
- Cash is expected to support current clinical and operational activities into early 2027.
- Research and Development expenses decreased to $16.5 million in Q1 2026 from $25.3 million in Q1 2025.
- Net loss for Q1 2026 was $20.7 million, down from $28.8 million in Q1 2025.
- Acumen expects to exercise its option to license two EBD program candidates in Q2 2026.